Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Avallone

Showing results (61-70 of 66) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 66 results.
ESMO Open|June 24, 2025
Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trialD Ciardiello, L Boscolo Bielo, F Pietrantonio, et al.
Techniques in Coloproctology|February 15, 2017
T1 colon cancer in the era of screening: risk factors and treatmentF Bianco, S De Franciscis, A Belli, et al.
ESMO Open|March 19, 2025
Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trialD Ciardiello, L Boscolo Bielo, S Napolitano, et al.
ESMO Open|October 29, 2025
Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapyL Boscolo Bielo, S Napolitano, A Avallone, et al.
ESMO Open|July 6, 2026
Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysisS Camera, A Vogel, M Rimini, et al.
ESMO Gastrointestinal Oncology|May 22, 2026
Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort studyH Vandeputte, A Casadei-Gardini, F Peeters, et al.
Pageof 7

Showing results (61-70 of 66) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 66 results.
ESMO Open|June 24, 2025
Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trialD Ciardiello, L Boscolo Bielo, F Pietrantonio, et al.
Techniques in Coloproctology|February 15, 2017
T1 colon cancer in the era of screening: risk factors and treatmentF Bianco, S De Franciscis, A Belli, et al.
ESMO Open|March 19, 2025
Comprehensive genomic profiling by liquid biopsy portrays metastatic colorectal cancer mutational landscape to predict antitumor efficacy of FOLFIRI plus cetuximab in the CAPRI-2 GOIM trialD Ciardiello, L Boscolo Bielo, S Napolitano, et al.
ESMO Open|October 29, 2025
Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapyL Boscolo Bielo, S Napolitano, A Avallone, et al.
ESMO Open|July 6, 2026
Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysisS Camera, A Vogel, M Rimini, et al.
ESMO Gastrointestinal Oncology|May 22, 2026
Baseline neutrophil-to-eosinophil ratio and neutrophil-to-lymphocyte ratio as prognostic markers in patients with unresectable biliary tract cancer treated with gemcitabine-cisplatin-durvalumab: an international, multicentre, retrospective cohort studyH Vandeputte, A Casadei-Gardini, F Peeters, et al.
Pageof 7